5232
Rasha Mosa Mosa Allam
Pharmacological studies on the antiproliferative effects of Fingolimod (FTY720) in prostate human cancer cells
Fingolimod (FTY720), prostate
Prostate cancer is the second most frequently occurring cancer in males, with approximately 1.1 million new diagnoses per year and is predicted to be the leading cause of cancer-related death in men over the next decade. Several studies demonstrated that estrogens, estrogen metabolites, estrogen receptors and estrogen receptor downstream signaling were involved in prostate cancer development and progression. Sphingolipids and sphingosine kinase 1 have emerged as new players in the tumor microenvironment and cancer progression during the last decade. Indeed, sphingolipids were added to the list of estrogen activated mediators, regulating diverse cellular processes important for estrogen related cancer progression. FTY720, the first clinically approved sphingosine kinase 1 inhibitor, has emerged as a key player in cancer therapy as it has shown antitumor efficacy both in vivo and in vitro in multiple types of cancer including prostate cancer.
2016
Ph.d
Ain Shams
Pharmacy